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Abstract 
Malignant melanoma in the esophagus is a rare condition which has been described only 
occasionally in case reports or in larger series of patients with esophageal disease. We 
describe here the very rare case of a patient who presented initially with a 2-month 
history of dysphagia and weight loss which led to the endoscopic diagnosis of an unclear 
lesion in the distal esophagus. Biopsies were taken revealing positive 
immunohistochemical staining against HMB-45. As there were no signs of skin melanoma 
and there was an absence of pigmentation, a diagnosis of primary amelanotic malignant 
melanoma was made. Primary staging of the lesion was completed with computed 
tomography (CT), which revealed a locally advanced tumor with lymph node metastases 
at the lesser curvature of the stomach and celiac trunk. As there is still a lack of potential 
protocols for multimodal neoadjuvant treatment for this rare tumor entity, a palliative 
abdominothoracic esophagectomy with systemic lymphadenectomy and intrathoracic 
anastomosis was carried out. Due to an intraoperative R2 situation, clip marking was 
performed to allow postoperative radiotherapy. Two months postoperatively, the 
planning CT scan for radiotherapy revealed progression of the retroperitoneal tumor 
mass, which was enclosing the celiac trunk, renal vein, and superior mesenteric artery. 
Multiple new liver and lung metastases were also found. During the following weeks, the 
patient developed acute renal failure and was admitted for dialysis, and the planned 
radiotherapy was deferred. At the end of May 2007, 4 months after the primary diagnosis, 
the patient died due to acute renal failure. 
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Introduction 
Primary malignant melanoma of the esophagus (PMME) is a very rare tumor entity. 
Exact incidence rates are not available, since only small series and case reports have been 
reported so far. Patients suffering from PMME are usually diagnosed at a late stage, as the 
lesion’s initial symptoms are nonspecific and challenging for any physician. In 
approximately 50% of cases in Western countries, esophageal neoplasms present at locally 
advanced tumor stages – the most frequent type being adenocarcinoma, ahead of 
squamous cell carcinoma. It has been estimated that approximately 0.1–0.2% of 
malignant esophageal tumors are malignant melanomas. Amelanotic PMME account for 
10–25% of melanomas in the esophagus [1]. The most frequently reported site for 
esophageal malignant melanoma is the distal part of the esophagus. Overlapping sites and 
unknown sites account for 26% of small bowel cancers. Neoplasms and malignant 
melanomas in the esophagus become overt when symptoms of dysphagia, odynophagia, 
weakness, or weight loss develop due to mechanical constriction. 
The pathogenesis of PMME is still unclear. In the mid-20th century, it was thought 
that the esophageal epithelium is devoid of melanoblasts, until in 1963 melanoblasts and 
granules, from which PMME is capable of developing, were described in the normal 
esophageal mucosa. Although the origin of the melanoblasts is still unclear, it appears that 
they migrate from the neural crest and later differentiate into melanocytes in the 
esophageal wall [2]. 
This report describes a case of locally advanced amelanotic PMME, with locoregional 
lymph node metastases. Postoperative radiotherapy was planned for the patient following 
a palliative R2 esophagectomy. A follow-up examination after 2 months revealed 
progression of the retroperitoneal tumor mass, which was enclosing the celiac trunk, renal 
vein, and superior mesenteric artery. Multiple new liver and lung metastases were also 
found. Four weeks later, the patient developed acute renal failure and died in May 2007 
after a short period of dialysis. 
Case Report 
Patient History and Diagnostic Procedures 
A 57-year-old man was admitted to the surgical department in January 2007 due to a 3-month 
history of dysphagia, odynophagia, and weight loss of 10 kg. His medical history included a 
thyroidectomy due to a toxic nodular goiter, smoking (10 pack-years), arterial hypertension, and an 
unremarkable family history. Examination showed no evidence of skin melanoma lesions. 
Esophagogastroduodenoscopy identified an ulcerated tumor, 7 cm in length, in the distal esophagus. 
Inspection of the tumor did not raise any suspicion of malignant melanoma (fig. 1a). 
Endoscopic ultrasound showed that the tumor was at a locally advanced stage (uT3 N+), with 
inhomogeneous tumor formation and cystic and solid components (fig. 1b). Biopsies were taken, 
revealing pleomorphic and hyperchromatic nuclei in the tumor cells and brown-black melanin 
pigmentation in the cytoplasm. Immunohistochemical staining was positive for HMB-45, MIB-1, and 
PAN melanoma marker Melan A, and negative for S100 protein and cytokeratin KL1. 
The further staging work-up included computed tomography of the chest and abdomen, tests for 
cardiac and pulmonary function, and laboratory tests, which were inconspicuous except for moderate 
left ventricular hypertrophy. Radiographic findings showed an eccentric tumor mass in the esophageal 
wall and enlarged lymph nodes in the mediastinum, at the lesser curvature of the stomach, and 
surrounding the celiac trunk (fig. 2).  
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Positron-emission tomography with 
18F-fluorodeoxyglucose (FDG-PET) correlated well with the 
computed tomography and revealed an accumulation of the tracer in the distal esophagus, the lesser 
curvature of the stomach, and the celiac trunk, with no other suspicious areas. A diagnosis of PMME 
was made. 
Surgery and Histopathology 
Following an interdisciplinary discussion, the decision was taken to carry out a palliative 
abdominothoracic esophagectomy with systematic lymphadenectomy and with an intrathoracic 
esophagogastric anastomosis. In addition, abdominal tumor debulking was planned, as well as 
intraoperative clip marking to allow postoperative radiotherapy, due to the high risk of a macroscopic 
R2 resection in the area of the celiac trunk. The surgical specimen contained the ulcerative tumor in the 
distal esophagus and distinct glymph node conglomerates. Neoplastic infiltration included the 
muscularis propria and marked tumor tissue around the celiac trunk. Histopathology showed tumor 
cells with highly atypic nuclei, prominent macronucleoli, and high mitosis rates. No pigment was 
observed in the areas examined. The lymph nodes were macroscopically suspicious for tumor invasion, 
and histopathology revealed tumor infiltration into the mediastinal lymph nodes (n = 10). Resection of 
the primary tumor was macroscopically and microscopically complete, while the lymph node 
conglomerate around the celiac trunk only allowed R2 resection. Immunohistochemical staining was 
positive for S100 (in contrast to the biopsies) and HMB-45, and was negative for CD45 and 
pancytokeratin. Histopathology established a diagnosis of amelanotic PMME (fig. 3). 
The postoperative course was uneventful, and the patient was discharged in good condition on the 
14th postoperative day. In view of the R2 situation (in the celiac trunk), a CT examination was carried 
out 2 months postoperatively, in March 2007, before the planned radiotherapy. The CT showed 
progression of the retroperitoneal tumor mass, enclosing the celiac trunk, renal vein, and superior 
mesenteric artery, as well as multiple liver and lung metastases. Four weeks later, the patient was 
admitted for dialysis due to acute renal failure, and he died in May 2007, 4 months after first being 
diagnosed with PMME. The relatives declined an autopsy. 
Discussion 
The first case of PMME was described by Baur in 1906 [3]; until now, 100 years later, 
only approximately 250 cases have been published in the worldwide literature [4]. PMME 
is a very rare tumor entity, representing only 0.1–0.2% of all esophageal malignancies [5]. 
Amelanotic PMME account for 10–25% of melanomas in the esophagus [2] and true 
amelanotic PMME, which show no melanin on histopathological examination, account 
for only 2% [6]. PMME occur mainly in the sixth and seventh decades of life, but may 
develop at any age, with a male-to-female ratio of 2:1 [4]. The patient described here was a 
57-year-old man. In over 90% of the reported cases, the lesions develop in the lower third 
of the esophagus. PMME are diagnosed at a late stage, when mechanical obstruction 
develops, and the patients present with symptoms of dysphagia, odynophagia, and weight 
loss, similar to the presentation in adenocarcinoma or squamous cell carcinoma of the 
esophagus. The patients usually have a symptomatic history lasting a mean of 3.5 months 
before a diagnosis is established [2]. In the case described here, the tumor was situated in 
the distal part of the esophagus, and the patient presented with a 3-month history of 
dysphagia, odynophagia, and weight loss. 
The procedure of choice in patients with symptoms of dysphagia or odynophagia is 
esophagogastroduodenoscopy, with biopsies being taken at the same time, and 
endoluminal ultrasonography to establish the extent of the tumor in the esophageal wall. 
Computed tomography is used to estimate local tumor growth and peritumoral lymph 
node enlargement and to exclude distant metastases. Another method of detecting tumor 
growth in malignant melanoma is FDG-PET. The advantage of this diagnostic tool is that 
it is able not only to detect metastatic disease and locoregional lymph node metastases,  
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but also makes it possible to monitor disease activity during chemotherapy or 
radiotherapy [7]. According to Crippa et al. [8], FDG-PET scanning has a sensitivity for 
detecting lymph node metastases that ranges from 83% (in lesions 6–10 mm in size) to 
100% (in lesions >10 mm). In the case presented here, FDG-PET and CT were both 
carried out. Gallium-67 single-photon emission computed tomography (SPECT) can also 
be used to image tumor size and potential metastases. 
Despite the poor prognosis [1], the treatment of choice in patients with PMME is 
surgical resection, causing a longer mean survival than chemo- or radiotherapy alone 
(14 months vs. 3 months) [4]. Uthoff et al. [9] reported no difference in the survival time 
(14.8 months, n = 85) with surgery in comparison with radiotherapy (14.9 months, 
n = 10), but this might have been due to the smaller number of patients treated with 
radiotherapy in the group described, and radiotherapy is not generally recommended as 
the primary treatment for PMME [9]. To date, four patients with 5-year survival have 
been reported, all of whom underwent surgical resection [5]; only one patient who 
received radiotherapy has been reported to have a 5-year survival [10]. 
If a total or near total esophagectomy is not possible due to the patient’s general 
condition, a local resection should be the therapy of choice, yielding a mean survival of 
9 months [2]. In the present case, an abdominothoracic esophagectomy with intrathoracic 
anastomosis was carried out, and postoperative radiotherapy was planned due to an R2 
resection. 
A neoadjuvant multimodal therapy protocol is not currently available for 
gastrointestinal malignant melanoma, but some authors have reported that preoperative 
chemotherapy with dacarbazine and interferon beta has a marked effect on esophageal 
melanoma [5]. Kato et al. [11] reported that postoperative adjuvant therapy with a 
combination of dacarbazine, nimustine, and vincristine was effective in a patient with 
lymph node metastases. 
PMME is clinically confirmed when no other skin lesions (e.g., in the eyes or anal 
mucosa) are found. In 1953, Allen and Spitz [12]
 defined the following diagnostic criteria 
for PMME: (1) typical histological pattern of melanoma, with melanin granules inside the 
tumor cells; (2) origin in an area of junctional changes in the squamous epithelium; (3) 
junctional activity with melanotic cells in the adjacent epithelium. 
More accurate pretreatment diagnosis is nowadays achieved with 
immunohistochemical staining, as PMME typically reacts positively to HMB-45 and S100 
protein and negatively to cytokeratin [4]. The case reported here met all of these criteria, 
despite the absence of melanin granules inside the tumor cells, and a histopathological 
diagnosis of amelanotic PMME was therefore made. Histopathological examination of the 
specimen revealed infiltration of tumor cells into the submucosal layer, as is usually 
reported in PMME. 
When there is an R2 resection, clip marking of the area is very helpful for the 
radiotherapist for identifying the location for radiotherapy, which usually consists of 35–
48 Gy for these patients. The prognosis for patients with PMME continues to be poor, 
with a reported mean survival period of approximately 13.5 months and an overall 
survival of 4% at 5 years [13]. Only six patients with a survival of more than 5 years have 
been reported in the literature [14], with 12 years being the longest reported survival 
period [13]. 
The follow-up examination after 2 months of the patient described here revealed 
progression of the retroperitoneal tumor mass, which was enclosing the celiac trunk, renal  
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vein, and superior mesenteric artery. Multiple new liver and lung metastases were also 
found. He died 4 months after first being diagnosed with PMME due to acute renal 
failiure. 
Due to the rareness of PMME, follow-up treatment for these patients has to be based 
on the guidelines for esophageal cancer in general [15], although the significance of 
postoperative radiotherapy or chemotherapy needs further investigation [8]. Until now, 
there are only a few cases of neoadjuvant treatment of PMME described in the literature 
in which either chemo- or radiotherapy [5, 14] was administered. Except in one case, 
where the patient already suffered from cerebral metastasis by the time of diagnosis, 
surgical resection was performed after neoadjuvant treatment. The mean survival period 
was 49.7 months, however, in two cases adjuvant chemotherapy was administered after 
surgical resection [14]. Excluding these two patients, who survived 132 and 88 months, 
the mean survival was definitely lower with 9.5 months but slightly better than the 
outcome after local resection. Taking this into account, neoadjuvant chemotherapy 
followed by total or near total esophagectomy and adjuvant chemotherapy may increase 
the patients’ mean survival considerably, however, more data is needed to prove these 
findings. 
In the field of adjuvant therapy, neither chemotherapy nor radiotherapy seem to show 
a significant effectiveness for the treatment of PMME compared to surgery alone [4]. At 
present, there are approximately 20 cases published in the literature
 [2], showing a mean 
survival of 15 months for patients treated with adjuvant chemotherapy and 19 months for 
adjuvant radiotherapy. Although not significantly effecting the mean survival of patients 
with PMME, some authors state that adjuvant radiotherapy is likely to be effective in 
preventing the probability of relapses [4]. 
As approximately 80–85% of the patients with PMME die due to/with a disseminated 
disease [4], surgical resection of local recurrence respectively distant metastasis plays only 
a minor role in the treatment concept. However, there are single cases described, where 
surgical resection of metastasis 2 years after the primary operation led to a disease-free 
follow-up of 5 to 38 months. 
In conclusion, PMME is a very rare neoplasm with a poor prognosis. In most of the 
reported cases, widespread disease is already present at the time of diagnosis. Since there 
is no reliable neoadjuvant treatment, surgical resection is the therapy of choice. At 
present, there are no definitive data regarding the effect of postoperative chemotherapy or 
radiotherapy on overall 5-year survival, although some authors have reported disease 
control after administration of chemoradiotherapy. 
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Fig. 1. a Esophagogastroduodenoscopy, showing an ulcerated tumor, 7 cm in length, in the distal part 
of the esophagus. b Endoscopic ultrasonography, showing a locally advanced tumor (uT3 N+). 
 
 
 
Fig. 2. Computed tomography, showing an eccentric tumor mass in the esophageal wall and enlarged 
lymph nodes in the mediastinum, lesser curvature of the stomach, and surrounding the celiac trunk. 
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Fig. 3. a Hematoxylin-eosin staining of the tumor, showing polymorphic nuclei, prominent 
macronucleoli, and mitosis. b Pancytokeratin staining is positive in the overlying epithelium and 
negative in the tumor. c There is strongly positive staining of the tumor cells for S100. d Positive 
staining of the tumor cells for HMB-45. 
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